Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

Advert Previous studies linked the drug to a rare eye condition known as non-arteritic anterior ischemic optic neuropathy ...

New research found a link between GLP-1 use in people with diabetes and an elevated chance of wet AMD, which can cause blindness.

A European health authority has found that medications containing semaglutide—such as Ozempic, Wegovy, and Rybelsus—can ...

Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide.

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

As more people resort to a new generation of drugs to achieve the perfect body, Leah Hardy examines the latest warnings over ...

The European Medicines Agency warns that Novo Nordisk's Ozempic and Wegovy may, in rare cases, cause NAION—a serious eye condition that can lead to vision loss. The EMA has asked the company to update ...

An Israeli study found patients taking Ozempic or similar weight-loss shots were twice as likely to suffer from a serious degenerative eye disease compared to those not on the medication.

Don’t be persuaded by the abundance of propaganda you see in ads, newspapers, magazines, TV, and the Internet. There is no ...

June 6 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision ...